drugset / Trial / NCT00148993

Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors

NCT00148993

Non-randomizedSingle-groupOpen-label

Summary

The goal of this study is to apply allogeneic tumor cell vaccination for immunotherapy in patients with micro-metastatic disease and/or in patients at high risk disease progression. The present study will use allogeneic tumor cell lines for tumor cell vaccines that share MHC determinants with the patient aiming to overcome possible restriction of antigen presentation.

Timeline

Start
1998-07
Primary completion
Completion
2005-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Tumor Cell Vaccine Vaccine

Indications